Gilead Sciences | GILD - Sales Revenues


Gilead Sciences reported $8.3B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.1B 1.48B Jun/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 24.4B 1.43B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.56B 110M Sep/2026
J&J USD 25.4B 89M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Moderna USD 100M 289M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 14.44B 2.49B Sep/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026